History

January 2018

Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities

Press release

Evofem Announces Closing Of Merger With Neothetics

Press release

October 2017

OCON Medical announces its new successful round of financing & arrival of Chemo Group as shareholder

Press release

Neothetics, Inc. and Evofem Biosciences, Inc. Announce Merger Agreement to Create Women’s Health Company

Press release

Syndax Announces $25 Million Registered Direct Offering of Common Stock

Press release

September 2017

Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares

Press release

May 2017

NovaMedica began construction of a pharmaceutical plant in the Kaluga regions

Press release

Syndax Announces Proposed Public Offering of Common Stock

Press release

April 2017

NovaMedica launched Technology Center to develop innovative drugs

Press release

Epic Sciences Announces Completion of $40 Million Series D Financing

Press release

January 2017

Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder

Press release

Atlas Genetics Raises $35m in Series D Fundraising

Press release

December 2016

Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index

Press release

Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer

Press release

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome

Press release

November 2016

Allergan Successfully Completes Tobira Therapeutics Acquisition

Press release

September 2016

Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH

Press release

July 2016

NovaMedica, our portfolio company, and Pfizer announce a strategic partnership in Russia

Press release

Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB's Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program

Press release

Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test to Predict Treatment Response in Metastatic Prostate Cancer

Press release

April 2016

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus

Press release

Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion

Press release

December 2015

Clearside Biomedical, Inc. Completes $20 Million Series C Financing

Press release

NovaMedica is starting construction of R&D Center for drug development using nanotechnologies

Press release

November 2015

Marinus Pharmaceuticals Announces Public Offering of Common Stock

Press release

First US Commercial Appointment - Atlas Genetics appoints Keith Stauffer as VP Sales & Marketing

Press release

October 2015

Our portfolio company Transcend Medical Submits Final Module of FDA Premarket Approval Application for the CyPass® Glaucoma Micro-Stent

Press release

September 2015

Our portfolio company Marinus Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA for Ganaxolone in Focal Onset Seizures

Press release

Atlas Genetics Ltd: Grant of Key US Patent

Press release

August 2015

Our portfolio company Syndax Raises $80 Million In Series C Financing

Press release

June 2015

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Press release

January 2015

Atlas Genetics reels in $20M in Series C round for rapid infectious disease tests

Publication

December 2014

RMI Partners has joined Series C round of financing in Transcend Medical, Inc., the company which has developed CyPass, a unique device for Minimally Invasive Glaucoma Surgery (MIGS)

September 2014

Clearside Biomedical, Inc. Completes $16 Million Series B Financing 

Press-release

July 2014

Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine

Press-release

February 2014

Miramar Labs Secures $10 Million in Series D Funding

Press-release

October 2013

NovaDigm Therapeutics Raises $14M Series B to Support Phase 2 Trial of NDV-3 Vaccine 

Press-release

July 2013

RusnanoMedInvest, Domain Associates and investor syndicate back ReVision Optics vision correction technology with $55 mln investment.

Press-release

Press about

December 2012

RusnanoMedInvest and Domain Associates to invest $93m in development of three next-generation pharmaceuticals.

Press-release

Press about

December 2012

Financing Deal of the Year Nominee: Rusnano/Domain and CoDa Therapeutics.

October 2012

IV Special autumn session WHAT'S GOING ON IN THE PHARMACEUTICAL MARKET: LEADERS IN SEARCH OF EFFICIENCY.

Vladimir Gurdus: In order to foster the development of an innovative pharmaceuticals sector in Russia, we need the support of a globally competitive network of venture investors in the sector here in Russia.

June 2012

St. Petersburg International Economic Forum - 2012

Leonid Melamed:  Isolated oases of narrowly focused innovation in life sciences are not the way forward for Russia and represent a temporary fix at best – what is needed to drive truly transformational change are fully-integrated life sciences innovation clusters supported by an ecosystem of research and development, finance and other key success factors and specialized skill sets.

June 2012

Announcement of the first RusnanoMedInvest transaction - acquisition of shares of CoDa Therapeutics, Inc. (USA. CoDa is developing Nexagon, an innovative chronic wound healing solution with targeted applications in diabetic foot ulcers, venous leg ulcers and other chronic wound pathologies.

Press-release

Press about

March 2012

RUSNANO JSC and U.S. venture fund Domain Associates announced the launch of their joint investment program, as a result of which RusnanoMedInvestwas founded. 

The agreement between RUSNANO JSC and Team Drive on the management and operation of the RusnanoMedInvest investment program was signed.

More information about RusnanoMedInvest

Press-release

Press about

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.